Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence.

The costimulatory molecule CD28 has a restricted tissue distribution and is expressed on T cells and some plasmacytoma cells. Although CD28 is constitutively expressed, its expression is transiently down-regulated following T cell activation and declines progressively with in vitro senescence. In vivo, CD8+ T cells and, less frequently, CD4+ T cells may completely lose CD28 surface expression during chronic infections and with aging. This correlates with changes of nuclear protein-binding activities to two motifs, site alpha and beta, within the CD28 minimal promoter. Both alpha- and beta-bound complexes are found only in lymphoid tissues, in CD28+ T cells, and in some transformed B cells. These complexes are coordinately expressed except during replicative senescence, which is characterized by the down-modulation of site beta- but not site alpha-binding activities. In contrast, T cell activation induces a parallel decline in both site alpha- and beta-binding activities. CD4+ and CD8+ T cells differ in their beta-binding profiles, which may explain the more pronounced down-regulation of CD28 in senescent CD8+ T cells. In vivo expanded CD4+CD28null and CD8+CD28null T cells uniformly lack alpha- and beta-bound complexes, resembling the pattern seen in chronically activated cells and not of senescent cells.

[1]  A. Vallejo,et al.  Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. , 1998, Journal of immunology.

[2]  C. Geisler,et al.  Two distinct pathways exist for down-regulation of the TCR. , 1998, Journal of immunology.

[3]  Martine,et al.  CD28, a marker associated with tumoral expansion in multiple myeloma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  C. Weyand,et al.  Functional properties of CD4+CD28− T cells in the aging immune system , 1998, Mechanisms of Ageing and Development.

[5]  Walker,et al.  Down‐regulation of CD28 via Fas (CD95): influence of CD28 on T‐cell apoptosis , 1998, Immunology.

[6]  A. Vallejo,et al.  Aging-related Deficiency of CD28 Expression in CD4+ T Cells Is Associated with the Loss of Gene-specific Nuclear Factor Binding Activity* , 1998, The Journal of Biological Chemistry.

[7]  Merino,et al.  Progressive decrease of CD8high+ CD28+ CD57− cells with ageing , 1998, Clinical and experimental immunology.

[8]  B. Klein,et al.  Malignant plasma cell lines express a functional CD28 molecule , 1998, Leukemia.

[9]  A. Balsari,et al.  Contribution of CD4+, CD8+CD28+, and CD8+CD28- T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection. , 1998, The Journal of clinical investigation.

[10]  G. Pawelec,et al.  Human T‐cell clones in long‐term culture as a model of immunosenescence , 1997, Immunological reviews.

[11]  L. Turka,et al.  Differential down-regulation of CD28 by B7-1 and B7-2 engagement. , 1997, Transplantation.

[12]  L. Tuosto,et al.  Quantitative Contribution of CD4 and CD8 to T Cell Antigen Receptor Serial Triggering , 1997, The Journal of experimental medicine.

[13]  R. Effros Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. , 1997, Developmental and comparative immunology.

[14]  D. Schaid,et al.  Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. , 1997, Arthritis and rheumatism.

[15]  C. Weyand,et al.  Co‐stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28− T cells , 1997, European journal of immunology.

[16]  A. Minguela,et al.  CD28 expression on peripheral blood T lymphocytes after orthotopic liver transplant: upregulation in acute rejection. , 1997, Human immunology.

[17]  M. Hazzan,et al.  Recall response to cytomegalovirus in allograft recipients: mobilization of CD57+, CD28+ cells before expansion of CD57+, CD28- cells within the CD8+ T lymphocyte compartment. , 1997, Transplantation.

[18]  M. Jackson,et al.  Requirements for Peptide-induced T Cell Receptor Downregulation on Naive CD8+ T Cells , 1997, The Journal of experimental medicine.

[19]  T. Lloyd,et al.  Regulation of CD28 costimulation in human CD8+ T cells. , 1997, Journal of immunology.

[20]  P. Linsley,et al.  CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics , 1997, The Journal of experimental medicine.

[21]  L. Pease,et al.  The Locus-specific Enhancer Activity of the Class I Major Histocompatibility Complex Interferon-responsive Element Is Associated with a γ-Interferon (IFN)-inducible Factor Distinct from STAT1α, p48, and IFN Regulatory Factor-1* , 1996, The Journal of Biological Chemistry.

[22]  P. Linsley,et al.  Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions* , 1996, The Journal of Biological Chemistry.

[23]  C. Weyand,et al.  The Repertoire of CD4+ CD28− T Cells in Rheumatoid Arthritis , 1996, Molecular medicine.

[24]  C. Franceschi,et al.  Expansion of cytotoxic CD8+ CD28− T cells in healthy ageing people, including centenarians , 1996, Immunology.

[25]  M. Salmon,et al.  Factors that influence activated CD8+ T-cell apoptosis in patients with acute herpesvirus infections: loss of costimulatory molecules CD28, CD5 and CD6 but relative maintenance of Bax and Bcl-X expression. , 1996, Immunology.

[26]  I. Kariv,et al.  Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. , 1996, Journal of immunology.

[27]  P. Carlson,et al.  Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. , 1996, Arthritis and rheumatism.

[28]  P. Gregersen,et al.  Oligoclonality of CD8+ T cells in health and disease: aging, infection, or immune regulation? , 1996, Human immunology.

[29]  H. Ostrer,et al.  Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. , 1996, Journal of immunology.

[30]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[31]  G. Ahmann,et al.  Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. , 1996, Leukemia.

[32]  C. Weyand,et al.  CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. , 1996, The Journal of clinical investigation.

[33]  H. Volk,et al.  The enigma of CD57+CD28– T cell expansion—anergy or activation? , 1996, Clinical and experimental immunology.

[34]  O. Martins-Filho,et al.  Chagasic Patients Lack CD28 Expression on Many of Their Circulating T Lymphocytes , 1996, Scandinavian journal of immunology.

[35]  B. Barlogie,et al.  2Biological aspects of multiple myeloma , 1995 .

[36]  C. Thompson,et al.  CD28 and apoptosis. , 1995, Current opinion in immunology.

[37]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.

[38]  J. Ceuppens,et al.  Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down‐regulation on CD8+ T cells from HIV‐infected subjects , 1995, Clinical and experimental immunology.

[39]  R. Abraham,et al.  Protein-tyrosine kinase-dependent activation of STAT transcription factors in interleukin-2- or interleukin-4-stimulated T lymphocytes , 1995, Journal of Biological Chemistry.

[40]  L. Pease,et al.  Structure of the MHC A and B locus promoters in hominoids. Insights on the evolution of the class I MHC multigene family. , 1995, Journal of immunology.

[41]  P. Linsley,et al.  CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. , 1995, Research in immunology.

[42]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[43]  R. Effros,et al.  Decline in CD28+ T cells in centenarians and in long-term T cell cultures: A possible cause for both in vivo and in vitro immunosenescence , 1994, Experimental Gerontology.

[44]  P. Linsley,et al.  Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. , 1994, Journal of immunology.

[45]  C. Weyand,et al.  Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis. , 1994, The Journal of clinical investigation.

[46]  R. Bataille,et al.  Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. , 1994, Blood.

[47]  D N Posnett,et al.  Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy" [published erratum appears in J Exp Med 1994 Mar 1;179(3):1077] , 1994, The Journal of experimental medicine.

[48]  G. Ahmann,et al.  Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. , 1993, Cancer research.

[49]  J. Mcarthur,et al.  CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4 , 1993, The Journal of experimental medicine.

[50]  M. Marsh,et al.  Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56lck, increased association with clathrin- coated pits, and altered endosomal sorting , 1993, The Journal of experimental medicine.

[51]  K P Lee,et al.  Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.

[52]  P. Linsley,et al.  The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.

[53]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[54]  C. Thompson,et al.  The genomic organization of the CD28 gene. Implications for the regulation of CD28 mRNA expression and heterogeneity. , 1990, Journal of immunology.

[55]  C. Thompson,et al.  CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. , 1990, Journal of immunology.

[56]  C. Thompson,et al.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[57]  B. Seed,et al.  Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[58]  C. Fathman,et al.  Modulation of CD4 by antigenic activation. , 1987, Journal of immunology.

[59]  S. Hickman Benign monoclonal gammopathy. , 1982, Archives of internal medicine.